{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:40:38Z","timestamp":1788993638285,"version":"build-2803163510"},"reference-count":17,"publisher":"Royal College of Psychiatrists","issue":"2","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these communities might respond to these developments.<\/jats:p>","DOI":"10.1192\/bjp.2024.76","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T23:09:21Z","timestamp":1716160161000},"page":"308-310","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":16,"title":["Is it now time to prepare psychiatry for a psychedelic future?"],"prefix":"10.1192","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-1401","authenticated-orcid":false,"given":"David","family":"Nutt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Crome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-6952","authenticated-orcid":false,"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"S000712502400076X_ref1","unstructured":"1 Therapeutic Goods Administration (TGA). MDMA and Psilocybin Hub. Department of Health and Aged Care, Australian Government, 2023 (https:\/\/www.tga.gov.au\/products\/unapproved-therapeutic-goods\/mdma-and-psilocybin-hub)."},{"key":"S000712502400076X_ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"S000712502400076X_ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096"},{"key":"S000712502400076X_ref10","first-page":"619","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet"},{"key":"S000712502400076X_ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3"},{"key":"S000712502400076X_ref4","unstructured":"4 Price, S . Netherlands Establishes Commission to Investigate Medical Use of MDMA. Psychedelic Health, 2023 (https:\/\/psychedelichealth.co.uk\/2023\/04\/06\/netherlands-commission-investigate-MDMA\/)."},{"key":"S000712502400076X_ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"S000712502400076X_ref16","unstructured":"16 Hansard. H.C. Vol. 701, col. 785. (20 Oct 2021)."},{"key":"S000712502400076X_ref17","unstructured":"17 Davies, S . Cannabis Scheduling Review: Part 1. The Therapeutic and Medicinal Benefits of Cannabis-Based Products \u2013 a Review of Recent Evidence. Department of Health and Social Care, 2018 (https:\/\/www.gov.uk\/government\/publications\/cannabis-scheduling-review-part-1)."},{"key":"S000712502400076X_ref9","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.118.543.229"},{"key":"S000712502400076X_ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15841"},{"key":"S000712502400076X_ref3","unstructured":"3 Nutt, DJ , Young, AL , Rucker, J , Sesssa, B , Campbell, G , Martell, J , et al. 15 top psychiatrists ask the Royal College of Psychiatrists to support the request for the Home Office to reschedule psilocybin . Centre for Evidence Based Drug Policy, 2022 (https:\/\/static1.squarespace.com\/static\/65c76822a9336369874538ac\/t\/65fa12e50121ff39b45d526f\/1710887655882\/15+top+psychiatrists+ask+the+Royal+College+of+Psychiatrists+to+support+the+request+for+the+Home)."},{"key":"S000712502400076X_ref5","unstructured":"5 Scottish Medicines Consortium. Esketamine (Spravato). Scottish Medicines Consortium, 2020 (https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/esketamine-spravato-full-smc2258)."},{"key":"S000712502400076X_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.020"},{"key":"S000712502400076X_ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3530"},{"key":"S000712502400076X_ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02169-4"},{"key":"S000712502400076X_ref2","unstructured":"2 Heroic Hearts. Veterans. Heroic Hearts, 2023 (https:\/\/heroicheartsproject.org\/veterans\/)."}],"container-title":["The British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S000712502400076X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T06:46:59Z","timestamp":1728888419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S000712502400076X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S000712502400076X"],"URL":"https:\/\/doi.org\/10.1192\/bjp.2024.76","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}